NasdaqGS:IONS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$5.4b

Last Updated

2021/07/25 22:38 UTC

Data Sources

Company Financials +

Executive Summary

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. More Details


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Ionis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IONS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: IONS's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

4.0%

IONS

3.3%

US Biotechs

2.0%

US Market


1 Year Return

-35.5%

IONS

23.6%

US Biotechs

39.1%

US Market

Return vs Industry: IONS underperformed the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: IONS underperformed the US Market which returned 39.1% over the past year.


Shareholder returns

IONSIndustryMarket
7 Day4.0%3.3%2.0%
30 Day-2.3%2.1%1.6%
90 Day-12.8%4.7%3.5%
1 Year-35.5%-35.5%25.4%23.6%41.3%39.1%
3 Year-15.6%-15.6%15.5%10.4%64.0%53.8%
5 Year30.3%30.3%48.4%36.5%123.9%99.0%

Long-Term Price Volatility Vs. Market

How volatile is Ionis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ionis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IONS ($38.03) is trading below our estimate of fair value ($90.84)

Significantly Below Fair Value: IONS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IONS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IONS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IONS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IONS is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Ionis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

36.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IONS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IONS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IONS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IONS's revenue (17.6% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: IONS's revenue (17.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IONS's Return on Equity is forecast to be very high in 3 years time (42.8%).


Past Performance

How has Ionis Pharmaceuticals performed over the past 5 years?

10.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IONS is currently unprofitable.

Growing Profit Margin: IONS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IONS is unprofitable, but has reduced losses over the past 5 years at a rate of 10.8% per year.

Accelerating Growth: Unable to compare IONS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IONS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: IONS has a negative Return on Equity (-77.4%), as it is currently unprofitable.


Financial Health

How is Ionis Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: IONS's short term assets ($2.0B) exceed its short term liabilities ($295.1M).

Long Term Liabilities: IONS's short term assets ($2.0B) exceed its long term liabilities ($1.3B).


Debt to Equity History and Analysis

Debt Level: IONS's debt to equity ratio (134.9%) is considered high.

Reducing Debt: IONS's debt to equity ratio has reduced from 258% to 134.9% over the past 5 years.

Debt Coverage: IONS's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if IONS's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Ionis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IONS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IONS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IONS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IONS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IONS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Brett Monia (60 yo)

1.5yrs

Tenure

US$10,963,040

Compensation

Dr. Brett P. Monia, Ph.D., is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been its Chief Executive Officer since January 2020. He serves as Non-Executive Director at DYNACURE SAS since October...


CEO Compensation Analysis

Compensation vs Market: Brett's total compensation ($USD10.96M) is above average for companies of similar size in the US market ($USD6.50M).

Compensation vs Earnings: Brett's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IONS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: IONS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ionis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ionis Pharmaceuticals, Inc.
  • Ticker: IONS
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.361b
  • Shares outstanding: 140.96m
  • Website: https://www.ionispharma.com

Number of Employees


Location

  • Ionis Pharmaceuticals, Inc.
  • 2855 Gazelle Court
  • Carlsbad
  • California
  • 92010
  • United States

Listings


Biography

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/25 22:38
End of Day Share Price2021/07/23 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.